ImmunoGen, Inc. (NASDAQ:IMGN) [Trend Analysis] knocking active thrust in leading trading session, shares a decrease of -0.54% to 5.50 with around 2.79 Million shares have changed hands in this session. Immunogen reports clinical data from a 46-patient Phase 1 cohort evaluating the efficacy and safety of mirvetuximab soravtansine (IMGN). The firm reported the clinical data from a 46-patient Phase 1 cohort evaluating the efficacy and safety of mirvetuximab soravtansine as single-agent therapy for platinum-resistant, folate receptor alpha (FRa)-positive ovarian cancer.
Confirmed objective response rate of 44% and median progression-free survival of 6.7 months seen in cohort subset mirroring patient population selected for planned Phase 3 study. Company preparing to meet with FDA in early 3Q2016; targeting initiation of Phase 3 study in 4Q2016. The stock is going forward its fifty-two week low with 1.29% and lagging behind from its 52-week high price with -71.69%.
Likewise the positive performance for the quarter recorded as -24.86% and for the year was -36.19%, while the YTD performance remained at -59.47%. IMGN has Average True Range for 14 days of 0.43.
Shares of Depomed, Inc. (NASDAQ:DEPO) [Trend Analysis] swings enthusiastically in regular trading session, it an increase of 1.70% to close at $19.16. DepoMed (DEPO) updated on patent litigation. On May 18, Judge Claire C. Cecchi of the United States District Court for the District of New Jersey entered an order enjoining any of Actavis Elizabeth, Actavis LLC and Actavis, Alkem Laboratories Limited and Ascend Laboratories, Roxane Laboratories, and Watson Laboratories from marketing generic versions of any of NUCYNTA, NUCYNTA ER or NUCYNTA oral solution prior to the Court’s issuance of a decision in the pending patent litigation. DEPO is going forward its fifty-two week low with 56.41% and lagging behind from its 52-week high price with -43.21%. DEPO last month stock price volatility remained 5.56%.
Halcon Resources Corporation (NYSE:HK) [Trend Analysis] retains strong position in active trade, as shares scoring -4.30% to $0.97 in a active trade session, while looking at the shares volume, around 1.82 Million shares have changed hands in this session. Halcon Resources (HK) reached agreement to restructure balance sheet with select note holders for the potential elimination of $1.8 billion of debt & $222 million of preferred equity while reducing interest burden by more than $200 million.
The firm expects the RSA to be executed in the near term. Following the execution of the RSA, the Company plans to solicit the support of additional Affected Stakeholders for the Restructuring Plan. If certain voting thresholds are satisfied through the solicitation process, the Restructuring Plan will be executed through an accelerated pre-packaged Chapter 11 bankruptcy filing The firm has institutional ownership of 40.70%, while insider ownership included 2.70%. HK attains analyst recommendation of 3.40 with week’s performance of -7.94%. Investors looking further ahead will note that the Price to next year’s EPS is -907.10%.